European regulators have recommended efgartigimod be approved as an add-on therapy for adults with generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AChR) antibodies. This recommendation, from the Committee for Medicinal Products for Human Use (CHMP), will serve as the basis for a final regulatory decision from the…
News
Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, according to data from a small real-world U.S. study. Moreover, most patients discontinued maintenance immunomodulatory treatment. The study, “Safety and outcomes of eculizumab for acetylcholine…
Two molecules in blood cells may be potential biomarkers for diagnosing myasthenia gravis (MG), a study suggests. Researchers found levels to be lower in mononuclear cells — a mixture of different cell types that circulate in the bloodstream and have a round nucleus — of patients with MG than…
Two doses of the COVID-19 vaccine did not worsen symptoms in 200 people with myasthenia gravis (MG), with mostly injection site-related side-effects reported, matching those seen in the general population, a study reported. These findings contrast with those of a recent study suggesting that, in very rare cases,…
People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of life, but the disease’s human cost is rarely given adequate study, a systematic literature review has found. Symptoms generally eased following treatment and disease remission. Still, there is…
Medison Pharma has entered into a pact with the global immunology company Argenx to bring efgartigimod to market in Israel and across several European countries for treating adult patients with generalized myasthenia gravis (gMG). The agreement sets the stage for commercialization of efgartigimod in 14 countries: Hungary, Poland, Czech…
Vyvgart (efgartigimod alfa-fcab) is being made available to eligible adults with generalized myasthenia gravis (gMG) in the U.K. under an early access to medicines scheme (EAMS), Argenx, the therapy’s developer, announced. An EAMS is designed to enable access to potentially lifesaving medications for patients with unmet medical…
Myasthenia gravis (MG) affects 20 of every 100,000 people, according to the Myasthenia Gravis Foundation of America (MGFA), which is working to help educate the public about the rare disorder as part of this year’s MG Awareness Month. MG typically affects women under the age of 40 and…
A woman with repeat myasthenia gravis (MG) flares was found to have several rare and benign tumors in her heart, a case study reported. According to its scientists, this case highlights the importance of cardiac evaluations of MG patients, particularly those with recurring episodes of myasthenia…
A man developed myasthenia gravis (MG), which quickly progressed to an advanced stage, shortly after surgery to remove a tumor in the thymus gland, according to a report from China. Post-surgical MG is rare and its rapid severity even rarer, its scientists noted, and this man’s MG diagnosis was more…
Recent Posts
- MMF treatment may act faster than azathioprine for gMG: Study
- The pain of having myasthenia gravis is real, but there is joy in it, too
- Honoring those who care for others by ensuring no one is forgotten
- Thymectomy eases symptoms for children, teens with juvenile MG
- Real-world study finds Vyvgart often effective in gMG, but responses vary